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Phenomics is a systematic study of phenotypes on a genomewide scale that is expected to unravel, as of yet, unsuspected functional
roles of the genome. It remains to be determined how to optimally approach and analyze the available phenomics databases to
spearhead innovation in neuropsychiatry. By serendipitously connecting two unrelated phenotypes of increased blood levels of the
adipokine leptin, a molecule that regulates appetite, in 5-lipoxygenase- (5-LOX) deﬁcient mice and patients with a lower risk for
Alzheimer’s disease (AD), we postulated a leptin-mediated basis for beneﬁcial eﬀects of ALOX5 (a gene encoding 5-LOX) gene-
deﬁciency in AD. We suggest that it might be possible to avoid relying on serendipity and develop data-mining tools capable of
extracting from phenomics databases indications for such novel hypotheses. Hence, we provide an example of using a free-access
Arrowsmith two-node search interface to identify ALOX5 as unsuspected putative mechanisms for the previously described clinical
association between increased plasma levels of leptin and a lower risk of incident dementia and AD.
A narrow deﬁnition of “phenomics”i s“ as y s t e m a t i cs t u d y
of phenotypes on a genome-wide scale” [1]. Phenomics
has emerged as natural result of recent successes in high-
throughput genotyping. It is expected that phenomics
research would unravel, as of yet, unsuspected functional
roles of the genome. Notwithstanding some promise in
genetic linkage studies in the ﬁelds of neurology and
psychiatry, it has become a truism that neuropsychiatric
disorders are too complex to be caused by a single gene
disturbance.
Although new phenotypes are continuously being dis-
covered that can be associated with neuropsychiatric dis-
orders, it remains to be determined how to optimally
approach and analyze the available phenomics databases to
spearhead innovation in neuropsychiatry. Case in point is
the recent report of a curious association between increased
plasma levels of the adipokine leptin, a molecule that
regulates appetite, and a lower risk of incident dementia and
Alzheimer disease (AD) [2]. Although a number of genes
have been associated with AD, no obvious genetic marker
could account for the observed negative association between
increased plasma leptin and AD. Finding such a marker
w o u l do p e nn o v e ll i n e so fA Dr e s e a r c h .
With availability of cross-species genotype/phenotype
resources such as PhenomicDB (http://www.phenomicdb
.de/) one could beneﬁt from comparisons of human pheno-
types with those of experimental animal models. An obvious
question arises—is there a mouse gene knockout that leads
to increased plasma leptin levels and decreased AD-like
pathology? It would be helpful if one could address this
question in an interactive free-access phenomics database
such as PhenomicDB. However, using this database we were
unable to obtain a simple answer to the above hypothetical
question. As it often happens, serendipity pointed us into the
right direction. Through our previous research interest into
links between the inﬂammatory enzyme 5-lipoxygenase (5-
LOX) and AD [3],wewereawareofamouseknockoutmodel
inwhichALOX5gene,whichencodes5-LOX,hadbeenmade
deﬁcient. When this 5-LOX deﬁciency was transferred into a
transgenic mouse model of AD, the Tg2576, the amyloid-β
deposition in the brains of Tg2576 mice lacking 5-LOX, was
reduced by 64%–80% compared with Tg2576 controls [4].
Prompted by the ﬁndings of the AD-protective phenotype
of increased plasma leptin [2], we recalled that this leptin
phenotype was recently described in the ALOX5 mouse
knockout [5]. Thus, the same ALOX5 knockout that caused2 Cardiovascular Psychiatry and Neurology
a reduced AD-like pathology in mice [4] also increased their
plasma levels of leptin [5].
It might be possible to avoid relying on serendipity and
develop data-mining tools capable of extracting from phe-
nomics databases answers to questions similar to the one we
haveposedinthisarticle.Forexample,onecouldapplyatool
such as the Arrowsmith two-node search interface (http://
arrowsmith.psych.uic.edu/arrowsmith uic/index.html).This
tool has been developed to search articles in MEDLINE [6].
Brieﬂy, one inputs two separate PubMed queries, “A” and
“C”. Any articles present in both A and C are removed so
that the analysis will consider only indirect linkages between
the two sets. Then the software identiﬁes all words and 2-
and 3-word phrases found in the titles of the articles in
both A and C. These so-called B-terms are processed and
ranked according to the predicted probability that they will
be relevant in pointing to a meaningful link across the two
literatures. The user can further streamline the B-list, for
example, by selecting only the gene/protein names.
Hence, we used the free-access Arrowsmith interface to
test whether the ALOX5 gene could be discovered as a
new link between elevated plasma leptin levels and AD
by a PubMed search. We had chosen the advanced mode
and entered “increased plasma leptin” in search “A”. This
generated 2094 items. We entered “Alzheimer” in search “C”.
Thisgenerated53659items.Then,thesoftwaregeneratedthe
“B” list with 5030 items. We ﬁltered this list using the option
“semantics” by selecting “gene or protein names”. This
reduced the list to 359 items. To further reduce this number,
in the next step, we selected a ﬁlter termed “frequency”
and changed the default settings from “fewer” to “more”,
leaving the rest unchanged. This reduced the list to 41 items.
First on the list of genes/proteins was “ampk” (adenosine
monophosphate-activated protein kinase), and second was
“alox5” (other high-ranking genes/proteins were peptide
yy, Chop, matrix metalloproteinase MMP-2, phospholipid
transfer protein, and serum-glucocorticoid-inducible-kinase
1). Asking the software to identify literature associated with
“alox5” returned only two publications. One of them was the
paper on elevated plasma leptin in ALOX5 knockout mice
[5]. Thus, it appears that in this case we would have been
able to discover the 5-LOX-leptin-AD link without prior
knowledge about the leptin phenotype of ALOX5 knockout
mice. It has to be stressed that a simple use of PubMed,
that is, by entering together the three terms “leptin alox5
alzheimer” or “leptin 5-lipoxygenase Alzheimer” did not
generate any hits.
With this commentary, we have illustrated how phe-
nomics databases and data-mining interfaces can be used to
ﬁnd unsuspected links such as the example of a putative link
between 5-LOX, leptin, and AD. Follow-up research studies
are needed to understand the exact nature of such links. For
example, to explore whether 5-LOX deﬁciency could beneﬁt
ADpatientsnotonlyviathepreviouslysuggestedmechanism
that involves gamma secretase [4] but also in part due to 5-
LOX-mediated alterations of circulating leptin levels. Recent
studyhasidentiﬁedarolefor5-LOXpolymorphisminADin
a population from Northern Italy [7]. Based on similarities
between mouse and human phenotypes described in this
article, it appears that including leptin and 5-LOX in future
clinical studies with this and similar AD patient populations
is warranted.
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